{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:38:58Z","timestamp":1791952738155,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Background<\/jats:italic>\n                    In the Netherlands, home treatment with intravenous antimicrobial therapy is a relatively new concept. Although several studies have shown that outpatient parenteral antimicrobial therapy (OPAT) can be administered safely, people receiving antimicrobials at home remain at risk for adverse events, including readmission.\n                    <jats:italic>Aim<\/jats:italic>\n                    The aim of our retrospective study was to identify risk factors for readmission in patients discharged with OPAT.\u00a0\n                    <jats:italic>Method<\/jats:italic>\n                    Patients who were at least 18 years or older, discharged with OPAT\u00a0between\u00a0January 2016\u2013December 2018 were included. Variables that were\u00a0collected consisted of baseline demographics, complications, readmission within 30\u00a0days and treatment failure. Multivariate logistic regression analysis was performed to identify risk factors for readmission.\n                    <jats:italic>Results<\/jats:italic>\n                    A total of 247 patients were included; the most common reason for OPAT was bone and joint infections (17%). Penicillin (37%), cephalosporin (26%) and vancomycin\/aminoglycoside (15%) were the most commonly prescribed antimicrobials. Among patients receiving medication subject to therapeutic drug monitoring (i.e. aminoglycosides or vancomycin), 51% (19\/37) received weekly therapeutic drug monitoring. Receiving aminoglycosides or vancomycin (adjusted OR 2.05; 95% CI 1.30\u20133.25,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05) and infection of prosthetic material (adjusted OR 2.92, 95% CI 1.11\u20137.65,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05) were independent risk factors\u00a0associated with readmission.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    Although patients receiving medication subject to therapeutic drug monitoring are at higher risk of readmission, only half of the patients discharged with aminoglycosides or vancomycin were monitored according to IDSA guidelines. A specialized team in charge of monitoring patients with OPAT\u00a0is more\u00a0likely to increase the rate of monitoring to prevent readmissions and complications.\n                  <\/jats:p>","DOI":"10.1007\/s11096-022-01379-7","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T10:02:41Z","timestamp":1644832961000},"page":"557-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Risk factors for readmission among patients receiving outpatient parenteral antimicrobial therapy: a retrospective cohort study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-4627","authenticated-orcid":false,"given":"Sabrine","family":"Douiyeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jara R.","family":"de la Court","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Tuinte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdi","family":"Sombogaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier P.","family":"Schade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Kuijvenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanca","family":"Minderhoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim C. E.","family":"Sigaloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"1379_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/jac\/dkm210","volume":"60","author":"PC Matthews","year":"2007","unstructured":"Matthews PC, Conlon CP, Berendt AR, et al. Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother. 2007;60:356\u201362.","journal-title":"J Antimicrob Chemother"},{"key":"1379_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1086\/313755","volume":"30","author":"JR Dalovisio","year":"2000","unstructured":"Dalovisio JR, Juneau J, Baumgarten K, et al. Financial impact of a home intravenous antibiotic program on a medicare managed care program. Clin Infect Dis. 2000;30:639\u201342.","journal-title":"Clin Infect Dis"},{"key":"1379_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14737167.2019.1541404","volume":"19","author":"EM Psaltikidis","year":"2019","unstructured":"Psaltikidis EM, Silva END, Moretti ML, et al. Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system. Expert Rev Pharmacoecon Outcomes Res. 2019;19:341\u201352.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1379_CR4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s10096-017-2944-5","volume":"36","author":"L Saillen","year":"2017","unstructured":"Saillen L, Arensdorff L, Moulin E, et al. Patient satisfaction in an outpatient parenteral antimicrobial therapy (OPAT) unit practising predominantly self-administration of antibiotics with elastomeric pumps. Eur J Clin Microbiol Infect Dis. 2017;36:1387\u201392.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1379_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ijantimicag.2017.03.016","volume":"51","author":"OC Durojaiye","year":"2018","unstructured":"Durojaiye OC, Bell H, Andrews D, et al. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. Int J Antimicrob Agents. 2018;51:26\u201332.","journal-title":"Int J Antimicrob Agents"},{"key":"1379_CR6","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/cid\/cit920","volume":"58","author":"GM Allison","year":"2014","unstructured":"Allison GM, Muldoon EG, Kent DM, et al. Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy. Clin Infect Dis. 2014;58:812\u20139.","journal-title":"Clin Infect Dis"},{"key":"1379_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40360-018-0240-3","volume":"19","author":"V Huang","year":"2018","unstructured":"Huang V, Ruhe JJ, Lerner P, et al. Risk factors for readmission in patients discharged with outpatient parenteral antimicrobial therapy: a retrospective cohort study. BMC Pharmacol Toxicol. 2018;19:50.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1379_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/cid\/cix733","volume":"66","author":"SC Keller","year":"2018","unstructured":"Keller SC, Williams D, Gavgani M, et al. Rates of and risk factors for adverse drug events in outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2018;66:11\u20139.","journal-title":"Clin Infect Dis"},{"key":"1379_CR9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/phar.1799","volume":"36","author":"L Means","year":"2016","unstructured":"Means L, Bleasdale S, Sikka M, et al. Predictors of hospital readmission in patients receiving outpatient parenteral antimicrobial therapy. Pharmacotherapy. 2016;36:934\u20139.","journal-title":"Pharmacotherapy"},{"key":"1379_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciy867","volume":"68","author":"AH Norris","year":"2019","unstructured":"Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious diseases society of america clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2019;68:1\u20134.","journal-title":"Clin Infect Dis"},{"key":"1379_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11096-018-0751-4","volume":"41","author":"R Wijnakker","year":"2019","unstructured":"Wijnakker R, Visser LE, Schippers EF, et al. The impact of an infectious disease expert team on outpatient parenteral antimicrobial treatment in the Netherlands. Int J Clin Pharm. 2019;41:49\u201355.","journal-title":"Int J Clin Pharm"},{"key":"1379_CR12","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/jac\/dks193","volume":"67","author":"M Dryden","year":"2012","unstructured":"Dryden M, Saeed K, Townsend R, et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. J Antimicrob Chemother. 2012;67:2289\u201396.","journal-title":"J Antimicrob Chemother"},{"key":"1379_CR13","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1093\/jac\/dky294","volume":"73","author":"O Mansour","year":"2018","unstructured":"Mansour O, Heslin J, Townsend JL, et al. Impact of the implementation of a nurse-managed outpatient parenteral antibiotic therapy (OPAT) system in Baltimore: a case study demonstrating cost savings and reduction in re-admission rates. J Antimicrob Chemother. 2018;73:3181\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1379_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1345\/aph.1Q240","volume":"45","author":"BH Heintz","year":"2011","unstructured":"Heintz BH, Halilovic J, Christensen CL, et al. Impact of a multidisciplinary team review of potential outpatient parenteral antimicrobial therapy prior to discharge from an academic medical center. Ann Pharmacother. 2011;45:1329\u201337.","journal-title":"Ann Pharmacother"},{"key":"1379_CR15","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.2146\/ajhp150201","volume":"73","author":"EK Chung","year":"2016","unstructured":"Chung EK, Beeler CB, Muloma EW, et al. Development and implementation of a pharmacist-managed outpatient parenteral antimicrobial therapy program. Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm. 2016;73:e24-33.","journal-title":"Am J Health Syst Pharm AJHP Off J Am Soc Health Syst Pharm"},{"key":"1379_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.14423\/SMJ.0000000000000401","volume":"109","author":"KK Felder","year":"2016","unstructured":"Felder KK, Marshall LM, Vaz LE, et al. Risk factors for complications during outpatient parenteral antimicrobial therapy for adult orthopedic and neurosurgical infections. South Med J. 2016;109:53\u201360.","journal-title":"South Med J"},{"key":"1379_CR17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11999-009-0825-7","volume":"467","author":"A Duggal","year":"2009","unstructured":"Duggal A, Barsoum W, Schmitt SK, et al. Patients with prosthetic joint infection on IV antibiotics are at high risk for readmission. Clin Orthop Relat Res. 2009;467:1727\u201331.","journal-title":"Clin Orthop Relat Res"},{"key":"1379_CR18","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1093\/ofid\/ofu052.466","volume":"1","author":"N Shrestha","year":"2014","unstructured":"Shrestha N, Shrestha J, Everett A, et al. 758: treatment complications during outpatient parenteral antimicrobial therapy (OPAT) administered at home. Open Forum Infect Dis. 2014;1:S214.","journal-title":"Open Forum Infect Dis"},{"key":"1379_CR19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/0897190016688771","volume":"30","author":"CM Hale","year":"2017","unstructured":"Hale CM, Steele JM, Seabury RW, et al. Characterization of drug-related problems occurring in patients receiving outpatient antimicrobial therapy. J Pharm Pract. 2017;30:600\u20135.","journal-title":"J Pharm Pract"},{"key":"1379_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/jac\/dkt303","volume":"69","author":"D Huck","year":"2014","unstructured":"Huck D, Ginsberg JP, Gordon SM, et al. Association of laboratory test result availability and rehospitalizations in an outpatient parenteral antimicrobial therapy programme. J Antimicrob Chemother. 2014;69:228\u201333.","journal-title":"J Antimicrob Chemother"},{"key":"1379_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1177\/0897190014544786","volume":"28","author":"PJ Shah","year":"2015","unstructured":"Shah PJ, Bergman SJ, Graham DR, et al. Monitoring of outpatient parenteral antimicrobial therapy and implementation of clinical pharmacy services at a community hospital infusion unit. J Pharm Pract. 2015;28:462\u20138.","journal-title":"J Pharm Pract"},{"key":"1379_CR22","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/cid\/ciz362","volume":"70","author":"MAH Berrevoets","year":"2020","unstructured":"Berrevoets MAH, Ten Oever J, Oerlemans AJM, et al. Quality indicators for appropriate outpatient parenteral antimicrobial therapy in adults: a systematic review and RAND-modified Delphi procedure. Clin Infect Dis. 2020;70:1075\u201382.","journal-title":"Clin Infect Dis"},{"key":"1379_CR23","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1093\/jpids\/pix038","volume":"7","author":"AL Hersh","year":"2017","unstructured":"Hersh AL, Olson J, Stockmann C, et al. Impact of antimicrobial stewardship for pediatric outpatient parenteral antibiotic therapy. J Pediatr Infect Dis Soc. 2017;7:e34\u20136.","journal-title":"J Pediatr Infect Dis Soc"}],"updated-by":[{"DOI":"10.1007\/s11096-022-01393-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000}}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01379-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01379-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01379-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T21:09:38Z","timestamp":1650575378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01379-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1379"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01379-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1104099\/v1","asserted-by":"object"}]},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11096-022-01393-9","URL":"https:\/\/doi.org\/10.1007\/s11096-022-01393-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}